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Background: To make a radiobiological comparison, for high risk prostate cancer (T3a,
PSA > 20 ng/ml or Gleason > 7) of two radiotherapy treatment techniques. One technique
consists of a treatment in three phases of the pelvic nodes, vesicles and prostate using
a  conventional fractionation scheme of 2 Gy/fraction (SIMRT). The other technique consists
of  a treatment in two phases that gives simultaneously different dose levels in each phase,
2  Gy/fraction, 2.25 Gy/fraction and 2.5 Gy/fraction to the pelvic nodes, vesicles and prostate,
respectively (SIBIMRT).
Materials and methods: The equivalent dose at fractionation of 2 Gy (EQD2), calculated using
the  linear quadratic model with ˛/ˇprostate = 1.5 Gy, was the same for both treatment strate-
gies. For comparison the parameters employed were D95, mean dose and Tumour Control
Probabilities for prostate PTV and D15, D25, D35, D50, mean dose and Normal Tissue Com-
plication Probabilities for the rectum and bladder, with physical doses converted to EQD2.
Parameters were obtained for ˛/ˇprostate = 1.5, 3 and 10 Gy and for ˛/ˇoar = 1, 2, 3, 4, 6 and 8.
Results: For prostate PTV, both treatment strategies are equivalent for ˛/ˇprostate = 1.5 Gy but
for  higher ˛/ˇprostate, EQD2 and TCP, decrease for the SIBIMRT technique. For the rectum and
bladder when ˛/ˇoar ≤ 2 Gy, EQD2 and NTCP are lower for the SIMRT technique or equal in
both  techniques. For ˛/ˇoar ≥ 2–3 Gy, EQD2 and NTCP increase for the SIMRT treatment.
Conclusions: A comparison between two radiotherapy techniques is presented. The SIBIMRT
technique reduces EQD2 and NTCP for ˛/ˇoar from 2 to 8 Gy.
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cally, slowly proliferating prostate cancer cells are thought to
have a low ˛/  ˇ ratio; the ˛/  ˇ ratio of prostate carcinoma is
still being discussed but it is well known to be lower than the
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typical value of 10 Gy of most other solid tumours.2–4 This low
˛/ˇ value probably situated between 1.5 Gy and 3 Gy, suggests
that prostate cancer has high sensitivity to dose per fraction.
Therefore, a hypofractionated radiation delivery regimen, i.e.
a large radiation dose in a smaller number of fractions, should
be able to increase the therapeutic ratio.4–6 Furthermore, dose
escalation via hypofractionation may be biologically advanta-
geous in the event that surrounding critical organs such as
the bladder and rectum have lower sensitivity to fractionation
changes, with ˛/  ˇ ratio thought to be between 3 and 6 Gy.7,8
Usually, high risk prostate tumours are treated in sequen-
tial two-phase treatment with an initial irradiation of the
pelvic nodes, seminal vesicles and prostate followed by a
prostate boost, with doses ranging from 1.8 to 2 Gy per frac-
tion. Mohan et al.9 suggested a single-phase approach called
simultaneous integrated boost IMRT  (SIBIMRT) for head and
neck cancers which consists in delivering simultaneously dif-
ferent dose levels to different tissues in a single treatment
session. This technique increases simultaneously the target
dose conformality and the critical structure sparing.
1.1.  Aim
The aim of this study is to make a radiobiological com-
parison of an IMRT  treatment of the pelvic nodes, vesicles
and prostate in three phases (SIMRT), using a conventional
fractionation scheme of 2 Gy/fraction versus a treatment in
two phases that delivers different dose levels simultaneously
(SIBIMRT) in each phase. The SIBIMRT technique delivers a
higher dose per fraction to the prostate, 2.5 Gy/fraction, and
vesicles, 2.25 Gy/fraction, and the same dose as in the three
phases treatment to the pelvic nodes, 2 Gy/fraction.
2.  Materials  and  methods
2.1.  Patient  data
A non-randomised cohort of 20 patients with high-risk
prostate adenocarcinoma was selected. The eligible patients
had at least one of the following features: clinical Stage T3a
disease, prostate-speciﬁc antigen level >20 ng/ml, or Gleason
score >7. Two treatment strategies were evaluated for these
20 patients. The ﬁrst treatment modality (SIMRT) consisted of
three sequential phases: in the initial phase the pelvic nodes,
vesicles and prostate were irradiated to 46 Gy (23 fractions,
2 Gy/fraction), the second phase treated the prostate and vesi-
cles to 24 Gy (12 fractions, 2 Gy/fraction) and the last phase
treated the prostate to 12 Gy (6 fractions, 2 Gy/fraction). The
total physical doses were 46 Gy for the pelvic nodes, 70 Gy for
the vesicles and 82 Gy for the prostate.10
A different fractionation scheme was introduced11,12 for
the prostate and seminal vesicles hypofractionation with
the objective of improving a therapeutic ratio5 and reduc-
ing treatment time while achieving economical and patient
comfort beneﬁts. This second treatment strategy (SIBIMRT)
consisted of two phases. The ﬁrst phase treated simulta-
neously the pelvic nodes, seminal vesicles and prostate in 23
factions with doses of 46 Gy, 51.8 Gy and 57.5 Gy, respectively.
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2.25 Gy/fraction and 2.5 Gy/fraction, respectively. The second
phase treated simultaneously the vesicles and prostate in 6
fractions with doses of 13.5 Gy, 2.25 Gy/fraction, and 15 Gy,
2.5 Gy/fraction, respectively. The total physical doses for the
combination of the two phases were 46 Gy for pelvic nodes,
65.25 Gy for vesicles and 72.5 Gy for the prostate. Total doses
were calculated to obtain the same equivalent dose at frac-
tionation of 2 Gy (EQD2) for both treatment strategies, using
the linear quadratic model (LQ) with ˛/  ˇ = 1.5.
2.2.  Pre-treatment
Patients were instructed to have an empty bladder and rectum
for their CT-simulation and for each treatment appointment.
Bowel and rectum instructions involved the use of a sup-
pository or enema prior to CT-simulation and before each
treatment session. Also a dietary advice was given to patients
to prevent changes in the rectum size as much as possible.
2.3.  Contouring
The patients were scanned in a supine position in a Somatom
Sensation Open CT scanner (Siemens AG., Germany, Munich).
A knee rest and ankle support were used. The patients were
scanned from L3–L4 down to the top third of the femur in
3-mm slices. The prostate gland (P-CTV), proximal seminal
vesicles (SV-CTV), pelvic nodes (PN-CTV), bladder, rectum, and
femoral heads were contoured on the CT images with the radi-
ation therapy simulation system Advantage SIMTM MD 6.0.102
(GE Healthcare, Chalfont, and St. Giles, United Kingdom). The
prostate base was deﬁned on CT using bladder contrast. P-CTV
and SV-CTV were deﬁned as anatomical structures observed
in the CT images with no margins.
Prostate, vesicles and pelvic nodes planning target volumes
were generated (P-PTV, SV-PTV and PN-PTV, respectively). For
P-PTV and SV-PTV, a 6-mm margin was added to P-CTV and
SV-CTV respectively, in all directions. A margin of 1 cm in all
directions was added to PN-CTV to obtain PN-PTV. The mar-
gins are based on our experience in prostate movement  using
IGRT.13
Rectum was deﬁned from the anus to the sigmoid ﬂexure
and bladder was contoured entirely.
2.4.  Planning
Forward planning IMRT  was performed applying an in-house
developed prostate class solution.14 Plans were generated for
step and shoot delivery. The planning system employed was
Phillips Pinnacle 8.0 h (Phillips, Best, The Netherlands). Table 1
shows the treatment planning details.
The arrangement described in Table 1 provides a fast and
efﬁcient solution to the prostate case from the perspective
of planning and treatment delivery.14 Fig. 1 shows the total
summed dose distribution obtained in a transverse and coro-
nal plane for the SIMRT and for the SIBIMRT techniques.2.5.  Treatment
Patients were implanted with four gold seeds (3 mm long,
1 mm in diameter) in the prostate gland with the aid of
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Table 1 – Prostate class solution for each treatment phase.
First phase Second phase Third phase
Number and energy
of ﬁelds
10  18 MV ﬁelds 7 18 MV ﬁelds
Gantry angles 0◦ 30◦ 55◦ 95◦ 145◦
180◦ 215◦ 265◦ 305◦
330◦
0◦ 52◦ 95◦ 155◦ 205◦ 265◦ 308◦
Total segments SIMRT: 32 + 5 on
average to tailor the
plan to the
particular patient.
SIBIMRT: 32 + 5
previous
segments + 6 to
boost prostate.
SIMRT: 19 + 3 on
average to tailor the
plan to the
particular patient.
SIBIMRT: 19 + 3
previous
segments + 3 to
boost prostate.
SIMRT: 19 + 3 on
average to tailor the
plan to the
particular patient.
Types of segments Irradiate the whole planning target volume and improve homogeneity.
Block the intersection between PTV and organs at risk to achieve dose
constraints.
Increase ﬂuency near the OAR to compensate for ﬂuency lost due to
previous segments.
Compensate for the shape of the contour of the patient and for the
heterogeneities.
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Segments weights Based on the work of Arrans e
ltrasound medical equipment 1 week before the planning CT
can (two at the base, one at the apex, and one at the centre, as
symmetrically positioned as possible). The seeds were used
o position the prostate daily before treatment using the kV
mage-guided radiotherapy (IGRT) system (ExacTrac X-Ray6D).
.6.  Equivalent  dose  calculationso design the fractionation scheme of both treatment strate-
ies, the prescription dose to the prostate and vesicles using
he SIBIMRT technique was calculated to obtain the same
Fig. 1 – Isodose curves in a transverse and coronal plost prostate.
15]
EQD2 as for the SIMRT modality. Calculations of EQD2 were
done using the Linear Quadratic Model:
EQD2 = D ×
d + (˛/ˇ)
2 + (˛/ˇ)
where d is the dose per fraction, and D is the total physical
dose.In this study we used the value ˛/  ˇ = 1.5 to calculate
prescription doses for the SIBIMRT technique based on pre-
dictions of previous studies2–4 that indicate a low value for
the prostate ˛/ˇ.
ane for the SIMRT and the SIBIMRT techniques.
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Fig. 2 – Mean rectum EQD2 15, EQD2 25, EQD2 35 and EQD2 50 for SIMRT and SIBIMRT techniques and for ˛/ˇoar values of 1, 2
(a) 3, 4 (b) and 6, 8 Gy (c). The black and grey colours correspond to the lower and higher ˛/ˇoar values in each subﬁgure. For
each EQD2 the p value is indicated in the graph. (d) Mean rectum EQD2 for SIMRT and SIBIMRT techniques for ˛/ˇoar = 1, 2,
3,4, 6 and 8 Gy.
To compare dose distributions given at different dose per
fraction, EQD2 was calculated for each voxel separately in all
patients and for both treatment modalities. The cumulative
dose volume histograms (DVH) were obtained from these EQD2
dose distributions.
2.7.  Parameters
To compare both treatment modalities the parameters ana-
lyzed for the prostate PTV were D95 and mean dose with
physical doses converted to EQD2, i.e. EQD2 received by 95%
of volume (EQD2 95) and mean EQD2. These parameters were
calculated for ˛/ˇprostate values of 1.5, 3 and 10 Gy.
To compare both treatment modalities the parameters
selected for the rectum and bladder were those from RTOG
0415 (D15, D25, D35, D50 and mean dose) with physical doses
converted to EQD2, i.e. EQD2 received by 15%, 25%, 35% and
50% of the organ at risk volume (EQD2 15, EQD2 25, EQD2 35
and EQD2 50, respectively) and mean EQD2. These parameters
were calculated for ˛/ˇoar = 1, 2, 3, 4, 6 and 8.
Tumour Control Probabilities were calculated using a
Poisson-based model with the values of D50 and 50 estimated
in the work of Okunieff et al.16 and for ˛/ˇprostate = 1.5, 3 and
10 Gy.
Normal Tissue Complication Probabilities for the rec-
tum and bladder were calculated using the model of
Lyman–Kutcher–Burman (LKB).17–19 Parameters used in the
LKB model for bladder complications were n = 0.12, m = 0.15
and TD50 = 80 Gy from Lyman et al.17 and for the incidence of
late rectal bleeding complications were n = 0.084, m = 0.108 andTD50 = 78.4 Gy from Söhn et al.20 NTCP values were obtained
for ˛/ˇoar = 1, 2, 3, 4, 6 and 8.
2.8.  Statistical  analysis
A two-tailed paired t test was used two compare the treatment
strategies. The results were considered signiﬁcant at the 5%
level (p < 0.05).
3.  Results
Table 2 shows that for ˛/ˇprostate = 1.5 there is no signiﬁcant
difference for PTV EQD2 95 and mean EQD2 between SIBIMRT
and SIMRT modalities. However, for ˛/ˇprostate = 3 and 10 Gy
EQD2 95 and mean EQD2 are higher for the SIMRT case, the dif-
ference being higher for ˛/ˇprostate = 10 Gy. Table 2 also shows
that there is no difference in TCP between both techniques
for ˛/ˇprostate = 1.5, whereas for ˛/ˇprostate = 3 and 10 Gy, TCP is
higher in the 3 phases technique.
Fig. 2 shows that for ˛/ˇoar = 1 Gy there is no signiﬁcant
difference between both modalities for the rectum EQD2 15,
EQD2 25, EQD2 35, EQD2 50 and mean EQD2. However, for ˛/ˇoar
between 2 and 8 Gy those values increase in the SIMRT treat-
ment, the difference being higher when the ˛/ˇoar value rises.
A similar behaviour is found for the bladder. Fig. 3 shows
that for ˛/ˇoar = 1 Gy, bladder EQD2 15 is higher in the SIBIMRT
technique, whereas there is no signiﬁcant difference between
both modalities for bladder EQD2 25, EQD2 35, EQD2 50 and
mean EQD2. However, for ˛/ˇoar between 2 and 8 Gy these
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Table 2 – Mean value and standard deviation for EQD2 95, mean EQD2 and TCP for prostate PTV, ˛/  ˇ = 1.5 Gy, 3 Gy and
10 Gy for SIBIMRT and SIMRT modalities.
˛/  ˇ = 1.5 Gy ˛/  ˇ = 3 Gy ˛/  ˇ = 10 Gy
SIBIMRT SIMRT p SIBIMRT SIMRT p SIBIMRT SIMRT p
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8EQD295 (Gy) 79 ± 2 79 ± 2 0.6 77 ±
Mean EQD2 (Gy) 87 ± 1 86 ± 1 0.1 83 ±
TCP (%) 93.4 ± 0.5 93.0 ± 0.4 0.3 92.0 ±
alues increase in the SIMRT treatment, the difference being
igher with rising ˛/ˇoar values.
Fig. 4 shows that for ˛/ˇoar = 1 Gy rectum NTCP is lower
or the SIMRT than for the SIBIMRT treatment, while for
/ˇoar = 2 Gy no signiﬁcant difference was found between both
echniques. In contrast, for ˛/ˇoar ≥ 3 rectum NTCP increases
or the SIMRT technique. For bladder NTCP and ˛/ˇoar = 1 Gy,
o signiﬁcant difference was found between both techniques,
owever, for ˛/ˇoar ≥ 2 Gy, NTCP increases for the SIMRT tech-
ique. For both organs at risk the difference between both
reatments increases when ˛/ˇoar rises.
.  Discussion
he EQD2 calculations were done using the LQ model that can
e used if the following assumptions are made:
There is no repair of sublethal damage during irradiation.
2ang et al. reported a repair half time value of the prostate
f 16 min. For the bladder and rectum, the repair half time
ound in the literature is between 0.2 and 2 h.21 The prostate
reatment duration using external beam radiotherapy in our
ig. 3 – Mean bladder EQD2 15, EQD2 25, EQD2 35, EQD2 50 for SIM
, 4 (b) and 6, 8 (c). The black and grey colours correspond to the 
QD2 the p value is indicated in the graph. Mean bladder EQD2 fo
 Gy.79 ± 2 <0.05 73 ± 1 80 ± 1 <0.05
85 ± 1 <0.05 78 ± 1 85 ± 1 <0.05
93.0 ± 0.4 <0.05 89.6 ± 0.6 92.8 ± 0.3 <0.05
centre is around 5 min, therefore, it is a reasonable assump-
tion to neglect repair during irradiation. A longer treatment
time or a shorter repair half time would result in an EQD2
reduction.22,23 This would be advantageous for OARs in an
hypofractionated scheme but could decrease tumour control,
which is undesirable.
Sufﬁcient time is allowed for complete repair of sublethal
damage between fractions. In our centre the radiotherapy
treatment is fractionated with an interfraction interval of 1
day. In this case, this assumption is fully accomplished.2,21
There is no repopulation during the overall fractionated
radiotherapy treatment. This is a reasonable assumption for
prostate carcinoma which can be considered as a late-reacting
tissue in which little accelerated repopulation of clonogenic
tumour cells occurs during the RT course.24,25
There is a high uncertainty in the available data for radiobi-
ological parameters: sublethal repair half time, time after the
start of treatment when proliferation starts, etc. Also, many
assumptions are made in the LQ model. Therefore, EQD2 cal-
culations cannot be used as predictor outcomes for individual
patients. However, if a consistent set of parameters is man-
aged, as is the case of this work, EQD2 can be used for two
RT and SIBIMRT techniques and for ˛/ˇoar values of 1, 2 (a)
lower and higher ˛/ˇoar values in each subﬁgure. For each
r SIMRT and SIBIMRT techniques for ˛/ˇoar = 1, 2, 3, 4, 6 and
270  reports of practical oncology and rad
Fig. 4 – Rectum (a) and bladder (b) NTCP versus ˛/ˇoar with
˛/ˇoar = 1, 2, 3, 4, 6 and 8 Gy. For each NTCP the p value is
indicated in the graph.
terms of radiobiological parameter calculations to check if the
SIBIMRT is still superior to the SIMRT. Rising dose per frac-purposes: to design treatment strategies that should be tested
clinically in the future and to compare different modality
strategies with different fractionation.9
For NTCP and TCP calculations, there is no consensus on
the values used for the parameters n, m and TD50 for the LKB
model and D50 and 50 for the Poisson-based TCP model. Due
to the uncertainty in the model parameters, the NTCP and TCP
cannot be used as a conﬁdent predictor of organ at risk toxicity
or tumour control, however, they can be used for comparing
treatment modalities in a relative sense.18
The results obtained for prostate PTV indicate that if
˛/ˇprostate = 1.5 Gy both treatment techniques are equivalent in
terms of target coverage and TCP. This was expected because
˛/ˇprostate = 1.5 Gy is the value hypothesized in this work to
design the SIBIMRT treatment strategy. For higher ˛/ˇprostate
values, the dose per fraction has less effect over the resulting
EQD2, and it becomes more  similar to the physical dose. Con-
sequently, for ˛/ˇprostate higher than 1.5, SIMRT and SIBIMRT
are not equivalent and the last one results in less EQD2 to the
tumour. It has to be noted that the reduction in EQD295, mean
EQD2 and TCP is 2 Gy, 1 Gy and 1% for ˛/ˇprostate = 3 and 7 Gy,
7 Gy and 3.2% for ˛/ˇprostate = 10, therefore, for ˛/ˇprostate = 3 Gy,
although a signiﬁcant difference between both techniques
exist, this difference is very low.
It has been observed that for ˛/ˇoar = 1 Gy, EQD2 values for
the rectum and bladder are equivalent for both treatment
techniques or, in the case of EQD 15, superior for the SIMRT.2
However when ˛/ˇoar ≥ 2 Gy, EQD2 values for the SIMRT tech-
nique are higher.iotherapy 1 8 ( 2 0 1 3 ) 265–271
The EQD2 reduction for OARs for the SIBIMRT technique
is due to the combination of two facts. On one hand, when
the ˛/ˇoar value rises the resulting EQD2 is more  similar to the
physical dose which is lower for the SIBIMRT technique. There-
fore, it is natural to have a reduction in EQD2 given to OARs
when the ˛/ˇoar value rises. On the other hand, for ˛/ˇoar val-
ues as low as 2 Gy, EQD2 has also been observed to be lower.
The reason for this reduction could be the most conformal
dose distribution when designed to be delivered as a SIBIMRT.
When a treatment is planned to be delivered sequentially, tis-
sues irradiated during the large ﬁeld phase receive undesired
additional dose during the boost phase. Dose distributions of
SIBIMRT are signiﬁcantly superior in terms of conformality
because they are designed to simultaneously deliver different
dose levels to different tissues in a single treatment session
and the extra dose given to the tissues surrounding the boost
area is optimized to be as low as possible (Fig. 1).9
The results for ˛/ˇoar = 1 can be explained by the higher
dose per fraction to organs at risk of the SIBIMRT technique,
which results in EQD2 increasing for very low ˛/ˇoar values.
Despite of the improved dose conformality of this treatment
modality EQD2 given to OARs, when treating the prostate and
pelvic nodes simultaneously, is equivalent or in some cases
higher for the SIMRT technique. However, the ˛/ˇoar values
proposed in the literature for the rectum and bladder are
thought to be between 3 and 6 Gy.7,8 For these values, the
SIBIMRT technique is clearly superior to the SIMRT in terms of
dose to organs at risk.
The NTCPs show a similar tendency to the dosimetric
parameters. For ˛/ˇoar ≥ 3 Gy for the rectum and ˛/ˇoar ≥ 2 Gy
for the bladder, the EQD2 reduction that shows the SIBIMRT
technique results in a lower NTCP value. For ˛/ˇoar ≤ 2 Gy for
the rectum and ˛/ˇoar ≤ 1 Gy for the bladder, the higher dose
per fraction of the SIBIMRT affects the NTCP obtaining equiv-
alent values for both techniques or even a lower NTCP value
with the SIMRT technique. For the ˛/ˇoar values recommended
in the literature, i.e. between 3 and 6 Gy, there is an important
reduction in the NTCP values and, therefore, it is clearly more
advantageous to treat the patients with the SIBIMRT. Although
˛/ˇoar values are delimited in the literature, this work analy-
ses changes in EQD2 and NTCP for a wide range of ˛/ˇoar’s to
predict what could happen if the values referenced were not
exact or if they were different for a particular patient.
The results obtained for NTCP show a very high value for
the bladder. Although this value is improved with the SIBIMRT
technique it is still very high. Probably these high NTCP values
are due to high doses received in the intersection of the blad-
der and the PTV. A more  realistic value may be obtained if the
organ considered is the bladder without the intersection with
PTV. It is important to note that patients are treated with an
empty bladder.
A more  advantageous solution than the one used in this
work would be to treat the patients with the SIBIMRT tech-
nique in just one phase because it reduces treatment duration,
which beneﬁts the patient while reducing logistic and ﬁnan-
cial requirements. However, a new study should be done intion to prostate also increases dose per fraction to organs
at risk, which could increase EQD2 and NTCP values for low
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nd medium ˛/ˇoar values. Also, it would be difﬁcult to opti-
ize the dose to the pelvic nodes nearest to the prostate
TV and they would receive higher doses than the prescribed
ose.Conclusion
The current trend in prostate radiotherapy is hypofraction-
tion based on the low ˛/ˇprostate estimation of many  studies.5
n this work, a technique was introduced to hypofraction-
te prostate in high risk prostate cancer, which reduces or
chieves equal EQD2 and NTCP even for very low ˛/ˇoar values.
lso, for the ˛/ˇoar values proposed in the literature for the
ectum and bladder, there is a signiﬁcant reduction in EQD2
nd NTCP and this reduction is more  important for higher
/ˇoar values. Only in the improbable case of ˛/ˇoar = 1, rectum
TCP and EQD215 for the bladder are higher for the SIBIMRT
echnique.
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